The global cell cryopreservation market is estimated at USD 11.48 billion in 2024 and is forecasted to grow to USD 13.89 billion by 2025. By 2034, the market is projected to reach approximately USD 77.52 billion, showcasing a robust compound annual growth rate (CAGR) of 21.05% over the forecast period.
Cell cryopreservation is increasingly vital in various healthcare applications, driving strong market demand. With continuous advancements in medical research, the need for reliable cell preservation technologies is anticipated to surge significantly in the coming years.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5361
Cryopreservation is a vital technique used to maintain the integrity of cells by storing biological material at freezing temperatures, effectively putting it in a state of suspended animation for long-term preservation. This method is widely used in various pharmaceutical applications, including preserving hematopoietic tissue for transplants and pluripotent stem cells for in vitro fertilization.
The field of cryobiology has greatly contributed to advancements in medicine, particularly in the development of biologics like vaccines, by enabling the long-term storage of cell lines. Cryopreservation also plays a critical role in biotechnology, clinical testing, and research. It supports innovative therapies, such as autologous stem cell treatments, by preserving essential cells like those extracted from bone marrow for future use.
The cell cryopreservation market is witnessing significant investment and innovation. In June 2024, Acorn Biolabs, a Toronto-based biotechnology company specializing in stem cell freezing for regenerative medicine therapies, announced a Series A funding round of $11 million CAD (approximately $8 million USD). This funding, raised through multiple closings, highlights growing confidence in cell preservation technologies.
Similarly, in March 2024, CryoLogyx, a spinout from the University of Warwick, completed an oversubscribed seed funding round. The company, which aims to revolutionize cell science through cryopreservation, secured £500,000 GBP from the Wider Oxford Technology Angel Network (WOTAN), supported by investors like Oxford Technology Management and private UK business angels. These developments underscore the market’s dynamic growth and the increasing interest in cryopreservation innovation.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cell-cryopreservation-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5361
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More
Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More
Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More
Canada and the UK have joined forces in a groundbreaking project aimed at developing next-generation immunotherapies for malignant melanoma, a… Read More
The liquid filtration for pharmaceutical market is rapidly evolving and is poised to generate hundreds of millions in revenue between… Read More
The global ophthalmology devices market is valued at USD 7.51 billion in 2024 and is projected to grow to USD… Read More